Results

1–10 of 20 results for brolucizumab

Phase IIIb TALON study of brolucizumab versus aflibercept in a matched treat-and-extend regimen to treat neovascular AMD: 32-week primary outcomes
Carl D. Regillo, MD
Annual Meeting Talks
2022
Brolucizumab for the Treatment of Diabetic Macular Edema: 52-week Results from the KINGFISHER Study
On Demand Cases, Courses, and Papers
2022
Long-Term Real-World Safety and Efficacy Outcomes of Intravitreal Brolucizumab in the Management of Neovascular Age-related Macular Degeneration
On Demand Cases, Courses, and Papers
2022
Bilateral Effect Following Off Label Unilateral Intravitreal Brolucizumab Injection in a Patient With Pseudophakic Cystoid Macular Edema.
On Demand Cases, Courses, and Papers
2022
Maximum Consecutive Fluid Free Months and Its Association With Visual and Anatomical Outcomes in nAMD: A Post-Hoc Analysis From HAWK and HARRIER
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2021
Brolucizumab for the Treatment of Visual Impairment Due to Diabetic Macular Edema: 52-Week Results From the KESTREL and KITE Studies
David M. Brown, MD
Annual Meeting Talks
2021
Real World Experience of Brolucizumab for Persistent Macular Fluid in Neovascular Age-Related Macular Degeneration After Prior Anti-VEGF Treatments
Rehan M. Hussain, MD
Annual Meeting Talks
2021
Efficacy and Durability of Brolucizumab in Patients Being Transitioned From Prior Anti-VEGF Therapy
Scott D Walter, MD, MSc, FASRS
Annual Meeting Talks
2021
Number of Injections and Time to Dry Analysis of Brolucizumab Versus Aflibercept in Patients With Neovascular AMD: 96-Week Data From HAWK and HARRIER
Carl D. Regillo, MD
Annual Meeting Talks
2020
Brolucizumab for the treatment of visual impairment due to diabetic macular edema: 52-week results from the KITE and KESTREL studies
David M. Brown, MD
Updates from the Field
2021